Keratoconus is a progressive disease of the cornea, in which the cornea thins and takes on an irregular conical shape, affecting vision. Without treatment, it can progress to severe stages, where the only option is a corneal transplant.
Corneal Crosslinking (CXL) is a minimally invasive treatment that strengthens the cornea by applying riboflavin (vitamin B2) and ultraviolet-A (UVA) light. This procedure slows the progression of keratoconus by reinforcing the collagen fibers in the corneal tissue.
Crosslinking is recommended when there is evidence of keratoconus progression, which may include:
Increased corneal curvature (K1, K2, or Kmax)
Decreased corneal thickness (pachymetry)
Worsening vision or astigmatism
Notable changes in serial topographies
Young age (especially under 25 years of age)
Frequent eye rubbing (due to allergies, dryness, or other causes)
Family history of keratoconus
Presence of atopic diseases (asthma, dermatitis, etc.)
Improper contact lens wear
The corneal epithelium is removed (in most cases).
Riboflavin is applied for approximately 30 minutes.
The cornea is exposed to UVA light for 10-30 minutes, depending on the protocol.
This is an outpatient procedure performed in the operating room under topical anesthesia.
Significant eye pain for the first 48-72 hours. It can be moderate or severe and is controlled with oral pain relievers and eye drops.
Foreign body sensation, tearing, and sensitivity to light may occur.
Temporary vision loss, which gradually improves.
Attend with someone.
Do not wear makeup or creams around your eyes.
Wear sunglasses for the trip home.
Avoid rubbing your eyes.
Strictly follow postoperative instructions.
Use of topical antibiotics and anti-inflammatory drugs.
Use of therapeutic contact lenses for 5-7 days.
Do not touch or rub the treated eye.
Attend checkups on time.
Protect your eyes from the sun for several weeks.
Performing crosslinking early can prevent the need for a corneal transplant in the future. This procedure has been shown to halt progression in more than 90% of cases, preserving patients' vision and quality of life.